VEGFA and macular retinal edema: All 3 anti-VEGF agents caused a rapid decrease in OCT CST owing to macular edema–related CRVO during the mandated injection phase of this study, consistent with previous trials.3,4,5,9,14 There was an adjusted mean OCT CST increase at weeks 16 and 20 that was associated with fewer injections being administered, and thus the mean CST reductions were less than in SCORE 2 at 6 months (eg, aflibercept: SCORE2, –425 μm; LEAVO, –319 μm).